Skip to main content
. 2019 Sep 18;19:930. doi: 10.1186/s12885-019-5967-8

Fig. 6.

Fig. 6

The impact of Foxo3 expression on leukemia-free survival time of the AML patients. a Normal Karyotypic patients. b Non-Favorable patients. c non-M3 patients